Keytruda was the first immunotherapy called a checkpoint inhibitor that was approved for first‐line treatment of lung cancer. Below you’ll find common questions and answers about Keytruda to ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

However while melanoma is relatively rare, lung cancer is by far the UK’s biggest cancer killer. It causes 22% of all cancer deaths in men and women, more than breast and bowel cancer combined.

Merck & Co is pressing home its precious advantage over rival Bristol-Myers Squibb in first line lung cancer, announcing new figures from its checkpoint inhibitor Keytruda that suggest the drug ...

Merck & Co.’s drug Keytruda failed to help people with cancer in two clinical trials, both using the immunotherapy as an add-on to other types of treatment for early-stage lung and skin cancer ...

The Rahway, N.J., drugmaker, which was evaluating Keytruda in combination with maintenance Lynparza in a Phase 3 study in patients with metastatic squamous non-small cell lung cancer, said it is ...

Merck Keytruda combo fails lung cancer trial, sees another setback in prostate cancer Feb. 28, 2023 7:34 AM ET Merck & Co., Inc. (MRK) Stock PFE , AZN , ALPMF , ALPMY By: Ravikash Bakolia , SA ...

The phase III HARMONi-2 study evaluated ivonescimab monotherapy against Keytruda monotherapy as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC).

Keytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey — costing about $150,000 a year for a course of treatment. It’s approved for use with a specific test ...

The Food and Drug Administration (FDA) recently approved Keytruda (pembrolizumab) for patients with stage 1B, 2 or 3A non-small cell lung cancer that has been previously treated with surgery and ...

Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression.